Article Details
Retrieved on: 2024-11-02 18:03:59
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses recent developments in the biopharma sector related to biosimilars, including new approvals for ustekinumab, data supporting the safety of etanercept and infliximab biosimilars, and cost savings from adalimumab biosimilars.
Article found on: www.hcplive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here